诱导多潜能干细胞(iPSCs)的临床应用进展  

Clinical application progress of induced pluripotent stem cells(iPSCs)

作　　者：彭静[1] 黄聪[1] 蒋思文[1] 

机构地区：[1]华中农业大学动物科学技术学院动物遗传育种与繁殖教育部重点实验室,武汉430070

出　　处：《科学通报》2014年第9期763-768,共6页Chinese Science Bulletin

基　　金：国家转基因生物新品种培育重大专项(2011ZX08009-004)资助

摘　　要：诱导多潜能干细胞(induced pluripotent stem cells,iPSCs)自2006年被Yamanaka研究小组发现后,由于其与胚胎干细胞相似的分化潜能,且不涉及伦理问题,在临床研究等方面具有广阔的研究前景并迅速成为当前研究的热点.利用该技术能获得疾病特异的诱导多潜能干细胞,避免了移植中的免疫排斥问题,同时也可将其诱导分化为各种细胞类型并用于疾病模型的研究.本综述主要探讨iPS细胞的疾病模型和细胞治疗的研究进展,并就其存在的问题及应用前景进行浅析.Induced pluripotent stem cells （iPSCs） technology was pioneered by Yamanaka group in 2006. Because iPSCs show similar pluripotency as ESCs embryonic stem cells but without involving the ethical issues, they hold great promise in the field of clinical research and have become one of the current research focuses. The iPSCs derived from patients would generate disease-specific stem cells and thus avoid the immune rejection in transplantation, In addition, different disease models. This review will mainly focus on the research problems and application prospects are also discussed. they can be differentiated into various cell types to develop progress of iPSCs in cell therapy and disease models. The

关 键 词：诱导多潜能干细胞 疾病模型 细胞治疗 疾病特异性iPS细胞 

分 类 号：R457[医药卫生—治疗学]